ERBB2 and breast carcinoma: In another study of trastuzumab-resistant breast cancer, HER2-targeted CAR-T cells could infiltrate the core region of the tumor globule, showing tumor cell cytotoxic activity, whereas anti-HER2 antibodies failed.